Government-Owned Inventions; Availability for Licensing, 63841-63843 [2010-26160]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
are the source of IL–13, and are
activated by CD1 expressing intestinal
epithelial cells. Tissue removed from
UC patients were also shown to contain
increased numbers of nonclassical NKT
cells that produce markedly increased
amounts of IL–13. In addition, these
NKT cells are cytotoxic for epithelial
cells, supporting the concept that
epithelial damage is a key factor in UC.
Applications: Development of IL–13
and CD1 based therapeutics to treat or
prevent ulcerative colitis.
Development Status: Small animal
model studies.
Inventors: Warren Strober, Ivan Fuss,
Frank Heller, Richard Blumberg
(NIAID).
Related Publications:
1. IJ Fuss et al. Nonclassical CD1drestricted NK T cells that produce IL–13
characterize an atypical Th2 response in
ulcerative colitis. J Clin Invest. 2004
May;113(10):1490–1497. [PubMed:
15146247].
2. F Heller et al. Oxazolone colitis, a
Th2 colitis model resembling ulcerative
colitis, is mediated by IL–13-producing
NK–T cells. Immunity 2002
Nov;17(5):629–638. [PubMed:
12433369].
Patent Status:
• U.S. Patent No. 7,666,411 issued 23
Feb 2010 (HHS Reference No. E–131–
2002/0–US–02).
• U.S. Patent Application No. 12/
709,029 filed 19 Feb 2010 (HHS
Reference No. E–131–2002/0–US–10).
• International patent/patent
application filings.
Related Technologies: Related IBD
technologies also available for licensing
include IL–13 mutant and chimeric
molecules (HHS Reference No. E–003–
2005/0) and NF-kappa B decoy
oligonucleotides (HHS Reference No.
E–108–2005/0).
Licensing Status: Available for
licensing.
Licensing Contact: Sury Vepa, PhD,
J.D.; 301–435–5020;
vepas@mail.nih.gov.
Dated: October 12, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–26153 Filed 10–15–10; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
Federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUMMARY:
Mouse Anti-Mouse CXCL9 (Mig)
Monoclonal Antibodies
Description of Invention: This
technology describes monoclonal
antibodies against mouse chemokine
(C–X–C motif) ligand 9 (CXCL9), also
known as Monokine induced by gamma
interferon (Mig). CXCL9 is a secreted
protein that functions to attract white
cells and increased expression of CXCL9
has been linked to several diseases. The
inventors at the NIH generated over 100
anti-mouse CXCL9 antibodies from a
CLXL9/Mig knockout mouse and further
characterized several antibodies to show
neutralization of CXCL9. As such, these
antibodies could be used to measure
concentrations of mouse CLXL9 in
laboratory samples and block the
activity of CXCL9 in injected mice.
These antibodies are suitable for ELISA
and Western blot. The antibodies have
not been tested in flow cytometry or
immunohistochemistry, but may also be
useful for these applications.
Applications
• ELISA assays for detection and
measurement of CXCL9.
• Neutralization of CXCL9 activity in
mouse models and in vitro assays to
study the role of CXCL9 in immune
response and disease.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
63841
Advantages: Can be used in mice
without eliciting endogenous antibodies
reacting against the injected antiCXCL9.
Development Status: The technology
is currently in the pre-clinical stage of
development.
Inventors: Joshua M. Farber and
Hongwei H. Zhang (NIAID).
Patent Status: HHS Reference No.
E–198–2009/0—Research Tool. Patent
protection is not being pursued for this
technology.
Licensing Status
Available for licensing.
Licensing Contact: Whitney A.
Hastings; 301–451–7337;
hastingw@mail.nih.gov.
Signal-to-Noise Enhancement in
Imaging Applications Using a TimeSeries of Images
Description of Invention: The
invention offered for licensing relates to
the field of imaging and specifically to
the field of medical imaging. The
apparatus and method of the invention
provide for noise reduction in imaging
applications that use a time-series of
images. In one embodiment of the
invention, a time-series of images is
acquired using a same imaging protocol
of the same subject area, but the images
are spaced in time by one or more time
intervals (e.g., 1, 2, 3 * * * seconds
apart). A sub-region is projected across
all of the images to perform a localized
analysis (corresponding X–Y pixels or
X–Y–Z voxels are analyzed across all
images) that identifies temporal
components within each sub-region.
Subsequently, within the sub-regions,
only those temporal components are
selected whose amplitude is above a
predetermined amplitude threshold.
The images are then reconstructed using
the sub-regions with reduced
components. A maximal-intensityprojection (MIP) is applied in the
temporal domain (tMIP) in order to
obtain a single image with reduced
noise (this can be done either at the subregion level or at the reconstructed
image level). The technology can be
applied to a broad spectrum of medical
imaging technologies such as MRI, XRay, CT and others.
Applications: Medical imaging and
diagnostics applied to MRI, X-Ray, CT
scans or other imaging modalities
including PET, SPECT, ultrasound or
optical.
Advantages: Enhancing signal-tonoise of medical imaging techniques.
Development Status
• Proof of concept has been
demonstrated. Data is available.
E:\FR\FM\18OCN1.SGM
18OCN1
63842
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
• Need to acquire further data to
establish clinical utility of the method
and to further optimize the protocol.
Market
• According to market research
reports the market for medical imaging
equipment industry in the United States
is approximately $9.0 billion now and
has been growing by approximately
7.6% annually.
• The United States market for
computed tomography (CT) scanning
systems is estimated to touch $3.6
billion by the end of 2009. The U.S.
accounts for over 50.0% of the
worldwide market.
• Worldwide MRI equipment market
is estimated to reach $5.5 billion by
2010, according to new report by Global
Industry Analysts, Inc. (https://www.
strategyr.com/Magnetic_Resonance_
Imaging_MRI_Equipment_Market_
Report.asp). In the United States the
market for such equipment is estimated
at $1.9 billion for 2008, as stated the
same report. The very high-field MRI
systems market in the United States is
projected to reach $968 million by the
year 2010. Very High-Field Systems also
represent the fastest growing segment,
as hospitals and clinics upgrade old
equipment with state-of-the-art systems.
• Enhancements in imaging
technologies to achieve better image
clarity, reliability and speed are being
constantly pursued by medical imaging
companies. Technologies that offer such
improvements therefore present
excellent commercial potential. Thus
the subject invention which can be
applied in a broad spectrum of imaging
technologies offers such good
commercial potential.
Inventors: Han Wen and Vinay Pai
(NHLBI).
mstockstill on DSKH9S0YB1PROD with NOTICES
Relevant Articles
1. Fish DA, Grochmalicki J, Pike ER.
Scanning singular-value-decomposition
method for restoration of images with
space-variant blur. J Opt Soc Am A,
13(3), pp. 464–469, March 1996.
2. Du X, Dunxu Y, Cuihua L, Jing L.
‘‘A novel approach to SVD-based image
filtering improvement,’’ International
Conference on Computer Science and
Software Engineering, vol 6, pp. 133–
136, 2008.
Patent Status: U.S. Provisional
Application No. 61/266,442 filed 03 Dec
2009 (HHS Reference No. E–292–2009/
0–US–01).
Related Technologies: Image
denoising techniques such as singular
value decomposition (SVD).
Licensing Status: Available for
licensing.
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
Licensing Contacts
• Uri Reichman, PhD, MBA; 301–
435–4616; UR7a@nih.gov.
• John Stansberry, PhD; 301–435–
5236; stansbej@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung, and Blood
Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
implement the technology described
above on specific commercial platforms.
Please contact Denise Crooks, PhD at
301–435–0103 or via e-mail at
crooksd@nhlbi.nih.gov for more
information.
Inverse Agonists of the TSH Receptor
for the Treatment of Thyroid Cancer
and Hyperthyroidism
Description of Invention: This
technology features small molecule
inverse agonists of the thyroidstimulating hormone (TSH) receptor
that may be readily synthesized, and are
likely to prove effective for oral
administration. These compounds may
potentially be used to treat recurrent
thyroid cancer and some cases of
hyperthyroidism, and also represent
unique tools for investigating the role of
TSH receptor signaling in these
diseases.
According to the National Cancer
Institute, over 37,000 new cases of
thyroid cancer were diagnosed in the
United States in 2008. Approximately
10% to 30% of patients thought to be
disease-free after initial treatment will
develop recurrent cancer or metastases,
and unless the recurrence is detected
early, the prognosis is generally poor.
As the TSH receptor is known to
stimulate proliferation of thyroid cancer
cells, it has been suggested that
suppression of basal TSH receptor
signaling may improve outcomes in the
treatment of recurrent thyroid cancer.
The compounds disclosed in this
technology suppress basal signaling by
the TSH receptor, and are thus excellent
candidates for a suppression-based
treatment approach.
Applications
• Lead compounds for the
development of therapeutics for
recurrent or metastatic thyroid cancer.
• Lead compounds for the
development of therapeutics for
hyperthyroidism associated with
constitutive TSH receptor signaling.
• Tool for probing the role of basal
TSH signaling in normal endocrine
function and in disease states.
Development Status: In vitro studies
in primary human thyrocytes have been
performed.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Inventors: Marvin C. Gershengorn and
Susanne Neumann (NIDDK); Wenwei
Huang and Craig J. Thomas (NHGRI).
Relevant Publications
1. S Neumann, W Huang, E Eliseeva,
S Titus, CJ Thomas, MC Gershengorn. A
small molecule inverse agonist for the
human thyroid-stimulating hormone
receptor. Endocrinology. 2010
Jul;151(7):3454–3459. [PubMed:
20427476]
2. S Moore, H Jaeschke, G Kleinau, S
Neumann, S Costanzi, JK Jiang, J
Childress, BM Raaka, A Colson, R
Paschke, G Krause, CJ Thomas, MC
Gershengorn. Evaluation of smallmolecule modulators of the luteinizing
hormone/choriogonadotropin and
thyroid stimulating hormone receptors:
Structure-activity relationships and
selective binding patterns. J Med Chem.
2006 Jun 29;49(13):3888–3896.
[PubMed: 16789744]
3. S Neumann, G Kleinau, S Costanzi,
S Moore, BM Raaka, CJ Thomas, G
Krause, MC Gershengorn. A low
molecular weight antagonist for the
human thyrotropin receptor with
therapeutic potential for
hyperthyroidism. Endocrinology. 2008
Dec;149(12):5945–5950. [PubMed:
18669595]
Patent Status: U.S. Provisional
Application No. 61/322,138 filed 08 Apr
2010 (HHS Reference No. E–067–2010/
0–US–01).
Related Technologies
• HHS Reference No. E–223–2006/0.
• HHS Reference No. E–223–2006/1.
• HHS Reference No. E–284–2008/0.
Licensing Status: Available for
licensing.
Licensing Contact: Tara Kirby, PhD;
301–435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The NIDDK Office of Technology
Transfer and Development is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop inverse
agonists of the TAS receptor. Please
contact Marguerite J. Miller at 301–496–
9003 or millermarg@mail.nih.gov for
more information.
Small-Molecule TSH Receptor
Modulators for Diagnosis and
Treatment of Thyroid Disease and
Cancer
Description of Invention: NIH
investigators have discovered a series of
low molecular weight thyroidstimulating hormone (TSH) receptor
modulators for use in evaluation and
treatment of thyroid diseases, including
thyroid cancer, hypothyroidism, and
hyperthyroidism. Certain compounds
E:\FR\FM\18OCN1.SGM
18OCN1
Federal Register / Vol. 75, No. 200 / Monday, October 18, 2010 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
encompassed by this technology are
more potent and/or more specific TSH
receptor activators than currentlyavailable compounds; also, as small
molecules, these compounds are orally
available and are expected to be less
costly and more straightforward to
produce than recombinant protein
counterparts currently on the market.
According to the National Cancer
Institute, over 37,000 new cases of
thyroid cancer were diagnosed in the
United States in 2008, and over 1,500
people died of this disease. These
numbers reflect a progressive increase
in the incidence of thyroid cancer over
the last several years. Because most
cases of thyroid cancer are diagnosed in
patients between the ages of 20 and 54,
these patients will undergo decades of
follow-up monitoring after cancer
treatment. For the last decade,
recombinant TSH protein has been used
in this follow-up to increase detection
sensitivity for recurrent or metastatic
thyroid cancer, and to eliminate side
effects associated with withdrawal of
hormone replacement therapy. A smallmolecule TSH receptor agonist
encompassed by this technology would
have utility similar to recombinant TSH,
but would have several distinct
advantages. For example, as a small
molecule, rather than a recombinant
protein, such a compound would be
orally available, and would be less
difficult and expensive to produce.
These compounds are also more potent
and/or specific for the TSH receptor
than other known small-molecule TSH
receptor agonists. In addition to use in
thyroid cancer screening, these
compounds may also be useful for
adjunctive treatment (with radioactive
iodide) of thyroid cancer, and certain
forms of hypothyroidism.
Hyperthyroidism, or an overactive
thyroid gland, affects about 1% of
people in the United States and is often
caused by autoimmune over-stimulation
of the thyroid gland (Graves’ disease), or
by thyroid tumors. Drugs currently used
for treatment of hyperthyroidism inhibit
synthesis of thyroid hormones; the TSH
receptor antagonist compounds
encompassed by this technology have
the advantage of directly inhibiting
activity of the TSH receptor, rather than
inhibiting thyroid hormone synthesis.
Applications
• Diagnostic tools for evaluation and
treatment of thyroid cancer.
• Therapeutics for thyroid cancer,
hyperthyroidism, and hypothyroidism.
Market: Approximately 1 in 13
Americans suffers from a thyroid
disorder, and 10 million have a thyroid-
VerDate Mar<15>2010
16:45 Oct 15, 2010
Jkt 223001
related condition that requires ongoing
immunodiagnostic monitoring.
Development Status: Early stage.
Inventors: Marvin C. Gershengorn et
al. (NIDDK)
Publications
1. Moore S, Jaeschke H, Kleinau G,
Neumann S, Costanzi S, Jiang JK,
Childress J, Raaka BM, Colson A,
Paschke R, Krause G, Thomas CJ,
Gershengorn MC. Evaluation of smallmolecule modulators of the luteinizing
hormone/choriogonadotropin and
thyroid stimulating hormone receptors:
structure-activity relationships and
selective binding patterns. J Med Chem.
2006 Jun 29;49(13):3888–3896.
[PubMed: 16789744]
2. Neumann S, Kleinau G, Costanzi S,
Moore S, Raaka BM, Thomas CJ, Krause
G, Gershengorn MC. A low molecular
weight antagonist for the human
thyrotropin receptor with therapeutic
potential for hyperthyroidism.
Endocrinology 2008 Dec;149(12):5945–
5950. [PubMed: 18669595]
3. Unpublished data are also available
for review under a CDA.
Patent Status
HHS Reference Nos. E–223–2006/0
and E–223–2006/1—
• International Patent Application
No. PCT/US2007/011951 filed 17 May
2007, which published as WO 2007/
136776 on 29 Nov 2007
• National Phase entered in Australia,
Canada, Europe, Japan, and the United
States
HHS Reference No. E–284–2008/0—
• International Patent Application
No. PCT/US2008/011958 filed 20 Oct
2008.
Licensing Status: Available for
licensing.
Licensing Contact: Tara L. Kirby, PhD;
301–435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The NIDDK Clinical Endocrinology
Branch is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize small molecule TSH
receptor modulators. Please contact
Marguerite J. Miller at 301–496–9003 or
millermarg@mail.nih.gov for more
information.
63843
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of Minority Biomedical
Research Neuro Grant Applications.
Date: November 12, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency-Bethesda, 7400
Wisconsin Avenue, One Bethesda Metro
Center, Bethesda, MD 20814.
Contact Person: John J. Laffan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, Room 3AN18J, Bethesda,
MD 20892, 301–594–2773,
laffanjo@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: October 12, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–26185 Filed 10–15–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: October 12, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
National Institutes of Health
[FR Doc. 2010–26160 Filed 10–15–10; 8:45 am]
Notice is hereby given of a change in
the meeting of the National Institute of
BILLING CODE 4140–01–P
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
National Institute of Diabetes and
Digestive and Kidney Diseases;
Amended Notice of Meeting
E:\FR\FM\18OCN1.SGM
18OCN1
]]>Agencies
[Federal Register Volume 75, Number 200 (Monday, October 18, 2010)]
[Notices]
[Pages 63841-63843]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-26160]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies
Description of Invention: This technology describes monoclonal
antibodies against mouse chemokine (C-X-C motif) ligand 9 (CXCL9), also
known as Monokine induced by gamma interferon (Mig). CXCL9 is a
secreted protein that functions to attract white cells and increased
expression of CXCL9 has been linked to several diseases. The inventors
at the NIH generated over 100 anti-mouse CXCL9 antibodies from a CLXL9/
Mig knockout mouse and further characterized several antibodies to show
neutralization of CXCL9. As such, these antibodies could be used to
measure concentrations of mouse CLXL9 in laboratory samples and block
the activity of CXCL9 in injected mice. These antibodies are suitable
for ELISA and Western blot. The antibodies have not been tested in flow
cytometry or immunohistochemistry, but may also be useful for these
applications.
Applications
ELISA assays for detection and measurement of CXCL9.
Neutralization of CXCL9 activity in mouse models and in
vitro assays to study the role of CXCL9 in immune response and disease.
Advantages: Can be used in mice without eliciting endogenous
antibodies reacting against the injected anti-CXCL9.
Development Status: The technology is currently in the pre-clinical
stage of development.
Inventors: Joshua M. Farber and Hongwei H. Zhang (NIAID).
Patent Status: HHS Reference No. E-198-2009/0--Research Tool.
Patent protection is not being pursued for this technology.
Licensing Status
Available for licensing.
Licensing Contact: Whitney A. Hastings; 301-451-7337;
hastingw@mail.nih.gov.
Signal-to-Noise Enhancement in Imaging Applications Using a Time-Series
of Images
Description of Invention: The invention offered for licensing
relates to the field of imaging and specifically to the field of
medical imaging. The apparatus and method of the invention provide for
noise reduction in imaging applications that use a time-series of
images. In one embodiment of the invention, a time-series of images is
acquired using a same imaging protocol of the same subject area, but
the images are spaced in time by one or more time intervals (e.g., 1,
2, 3 * * * seconds apart). A sub-region is projected across all of the
images to perform a localized analysis (corresponding X-Y pixels or X-
Y-Z voxels are analyzed across all images) that identifies temporal
components within each sub-region. Subsequently, within the sub-
regions, only those temporal components are selected whose amplitude is
above a predetermined amplitude threshold. The images are then
reconstructed using the sub-regions with reduced components. A maximal-
intensity-projection (MIP) is applied in the temporal domain (tMIP) in
order to obtain a single image with reduced noise (this can be done
either at the sub-region level or at the reconstructed image level).
The technology can be applied to a broad spectrum of medical imaging
technologies such as MRI, X-Ray, CT and others.
Applications: Medical imaging and diagnostics applied to MRI, X-
Ray, CT scans or other imaging modalities including PET, SPECT,
ultrasound or optical.
Advantages: Enhancing signal-to-noise of medical imaging
techniques.
Development Status
Proof of concept has been demonstrated. Data is available.
[[Page 63842]]
Need to acquire further data to establish clinical utility
of the method and to further optimize the protocol.
Market
According to market research reports the market for
medical imaging equipment industry in the United States is
approximately $9.0 billion now and has been growing by approximately
7.6% annually.
The United States market for computed tomography (CT)
scanning systems is estimated to touch $3.6 billion by the end of 2009.
The U.S. accounts for over 50.0% of the worldwide market.
Worldwide MRI equipment market is estimated to reach $5.5
billion by 2010, according to new report by Global Industry Analysts,
Inc. (https://www.strategyr.com/Magnetic_Resonance_Imaging_MRI_Equipment_Market_Report.asp). In the United States the market for
such equipment is estimated at $1.9 billion for 2008, as stated the
same report. The very high-field MRI systems market in the United
States is projected to reach $968 million by the year 2010. Very High-
Field Systems also represent the fastest growing segment, as hospitals
and clinics upgrade old equipment with state-of-the-art systems.
Enhancements in imaging technologies to achieve better
image clarity, reliability and speed are being constantly pursued by
medical imaging companies. Technologies that offer such improvements
therefore present excellent commercial potential. Thus the subject
invention which can be applied in a broad spectrum of imaging
technologies offers such good commercial potential.
Inventors: Han Wen and Vinay Pai (NHLBI).
Relevant Articles
1. Fish DA, Grochmalicki J, Pike ER. Scanning singular-value-
decomposition method for restoration of images with space-variant blur.
J Opt Soc Am A, 13(3), pp. 464-469, March 1996.
2. Du X, Dunxu Y, Cuihua L, Jing L. ``A novel approach to SVD-based
image filtering improvement,'' International Conference on Computer
Science and Software Engineering, vol 6, pp. 133-136, 2008.
Patent Status: U.S. Provisional Application No. 61/266,442 filed 03
Dec 2009 (HHS Reference No. E-292-2009/0-US-01).
Related Technologies: Image denoising techniques such as singular
value decomposition (SVD).
Licensing Status: Available for licensing.
Licensing Contacts
Uri Reichman, PhD, MBA; 301-435-4616; UR7a@nih.gov.
John Stansberry, PhD; 301-435-5236; stansbej@mail.nih.gov.
Collaborative Research Opportunity: The National Heart, Lung, and
Blood Institute is seeking statements of capability or interest from
parties interested in collaborative research to implement the
technology described above on specific commercial platforms. Please
contact Denise Crooks, PhD at 301-435-0103 or via e-mail at
crooksd@nhlbi.nih.gov for more information.
Inverse Agonists of the TSH Receptor for the Treatment of Thyroid
Cancer and Hyperthyroidism
Description of Invention: This technology features small molecule
inverse agonists of the thyroid-stimulating hormone (TSH) receptor that
may be readily synthesized, and are likely to prove effective for oral
administration. These compounds may potentially be used to treat
recurrent thyroid cancer and some cases of hyperthyroidism, and also
represent unique tools for investigating the role of TSH receptor
signaling in these diseases.
According to the National Cancer Institute, over 37,000 new cases
of thyroid cancer were diagnosed in the United States in 2008.
Approximately 10% to 30% of patients thought to be disease-free after
initial treatment will develop recurrent cancer or metastases, and
unless the recurrence is detected early, the prognosis is generally
poor.
As the TSH receptor is known to stimulate proliferation of thyroid
cancer cells, it has been suggested that suppression of basal TSH
receptor signaling may improve outcomes in the treatment of recurrent
thyroid cancer. The compounds disclosed in this technology suppress
basal signaling by the TSH receptor, and are thus excellent candidates
for a suppression-based treatment approach.
Applications
Lead compounds for the development of therapeutics for
recurrent or metastatic thyroid cancer.
Lead compounds for the development of therapeutics for
hyperthyroidism associated with constitutive TSH receptor signaling.
Tool for probing the role of basal TSH signaling in normal
endocrine function and in disease states.
Development Status: In vitro studies in primary human thyrocytes
have been performed.
Inventors: Marvin C. Gershengorn and Susanne Neumann (NIDDK);
Wenwei Huang and Craig J. Thomas (NHGRI).
Relevant Publications
1. S Neumann, W Huang, E Eliseeva, S Titus, CJ Thomas, MC
Gershengorn. A small molecule inverse agonist for the human thyroid-
stimulating hormone receptor. Endocrinology. 2010 Jul;151(7):3454-3459.
[PubMed: 20427476]
2. S Moore, H Jaeschke, G Kleinau, S Neumann, S Costanzi, JK Jiang,
J Childress, BM Raaka, A Colson, R Paschke, G Krause, CJ Thomas, MC
Gershengorn. Evaluation of small-molecule modulators of the luteinizing
hormone/choriogonadotropin and thyroid stimulating hormone receptors:
Structure-activity relationships and selective binding patterns. J Med
Chem. 2006 Jun 29;49(13):3888-3896. [PubMed: 16789744]
3. S Neumann, G Kleinau, S Costanzi, S Moore, BM Raaka, CJ Thomas,
G Krause, MC Gershengorn. A low molecular weight antagonist for the
human thyrotropin receptor with therapeutic potential for
hyperthyroidism. Endocrinology. 2008 Dec;149(12):5945-5950. [PubMed:
18669595]
Patent Status: U.S. Provisional Application No. 61/322,138 filed 08
Apr 2010 (HHS Reference No. E-067-2010/0-US-01).
Related Technologies
HHS Reference No. E-223-2006/0.
HHS Reference No. E-223-2006/1.
HHS Reference No. E-284-2008/0.
Licensing Status: Available for licensing.
Licensing Contact: Tara Kirby, PhD; 301-435-4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity: The NIDDK Office of Technology
Transfer and Development is seeking statements of capability or
interest from parties interested in collaborative research to further
develop inverse agonists of the TAS receptor. Please contact Marguerite
J. Miller at 301-496-9003 or millermarg@mail.nih.gov for more
information.
Small-Molecule TSH Receptor Modulators for Diagnosis and Treatment of
Thyroid Disease and Cancer
Description of Invention: NIH investigators have discovered a
series of low molecular weight thyroid-stimulating hormone (TSH)
receptor modulators for use in evaluation and treatment of thyroid
diseases, including thyroid cancer, hypothyroidism, and
hyperthyroidism. Certain compounds
[[Page 63843]]
encompassed by this technology are more potent and/or more specific TSH
receptor activators than currently-available compounds; also, as small
molecules, these compounds are orally available and are expected to be
less costly and more straightforward to produce than recombinant
protein counterparts currently on the market.
According to the National Cancer Institute, over 37,000 new cases
of thyroid cancer were diagnosed in the United States in 2008, and over
1,500 people died of this disease. These numbers reflect a progressive
increase in the incidence of thyroid cancer over the last several
years. Because most cases of thyroid cancer are diagnosed in patients
between the ages of 20 and 54, these patients will undergo decades of
follow-up monitoring after cancer treatment. For the last decade,
recombinant TSH protein has been used in this follow-up to increase
detection sensitivity for recurrent or metastatic thyroid cancer, and
to eliminate side effects associated with withdrawal of hormone
replacement therapy. A small-molecule TSH receptor agonist encompassed
by this technology would have utility similar to recombinant TSH, but
would have several distinct advantages. For example, as a small
molecule, rather than a recombinant protein, such a compound would be
orally available, and would be less difficult and expensive to produce.
These compounds are also more potent and/or specific for the TSH
receptor than other known small-molecule TSH receptor agonists. In
addition to use in thyroid cancer screening, these compounds may also
be useful for adjunctive treatment (with radioactive iodide) of thyroid
cancer, and certain forms of hypothyroidism.
Hyperthyroidism, or an overactive thyroid gland, affects about 1%
of people in the United States and is often caused by autoimmune over-
stimulation of the thyroid gland (Graves' disease), or by thyroid
tumors. Drugs currently used for treatment of hyperthyroidism inhibit
synthesis of thyroid hormones; the TSH receptor antagonist compounds
encompassed by this technology have the advantage of directly
inhibiting activity of the TSH receptor, rather than inhibiting thyroid
hormone synthesis.
Applications
Diagnostic tools for evaluation and treatment of thyroid
cancer.
Therapeutics for thyroid cancer, hyperthyroidism, and
hypothyroidism.
Market: Approximately 1 in 13 Americans suffers from a thyroid
disorder, and 10 million have a thyroid-related condition that requires
ongoing immunodiagnostic monitoring.
Development Status: Early stage.
Inventors: Marvin C. Gershengorn et al. (NIDDK)
Publications
1. Moore S, Jaeschke H, Kleinau G, Neumann S, Costanzi S, Jiang JK,
Childress J, Raaka BM, Colson A, Paschke R, Krause G, Thomas CJ,
Gershengorn MC. Evaluation of small-molecule modulators of the
luteinizing hormone/choriogonadotropin and thyroid stimulating hormone
receptors: structure-activity relationships and selective binding
patterns. J Med Chem. 2006 Jun 29;49(13):3888-3896. [PubMed: 16789744]
2. Neumann S, Kleinau G, Costanzi S, Moore S, Raaka BM, Thomas CJ,
Krause G, Gershengorn MC. A low molecular weight antagonist for the
human thyrotropin receptor with therapeutic potential for
hyperthyroidism. Endocrinology 2008 Dec;149(12):5945-5950. [PubMed:
18669595]
3. Unpublished data are also available for review under a CDA.
Patent Status
HHS Reference Nos. E-223-2006/0 and E-223-2006/1--
International Patent Application No. PCT/US2007/011951
filed 17 May 2007, which published as WO 2007/136776 on 29 Nov 2007
National Phase entered in Australia, Canada, Europe,
Japan, and the United States
HHS Reference No. E-284-2008/0--
International Patent Application No. PCT/US2008/011958
filed 20 Oct 2008.
Licensing Status: Available for licensing.
Licensing Contact: Tara L. Kirby, PhD; 301-435-4426;
tarak@mail.nih.gov.
Collaborative Research Opportunity: The NIDDK Clinical
Endocrinology Branch is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize small molecule TSH receptor modulators.
Please contact Marguerite J. Miller at 301-496-9003 or
millermarg@mail.nih.gov for more information.
Dated: October 12, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2010-26160 Filed 10-15-10; 8:45 am]
BILLING CODE 4140-01-P
